Kate Esselen, MD, MBA

Beth Israel Deaconess Medical Center

Academic Titles

Assistant Professor, Obstetrics, Gynecology and Reproductive Biology, Harvard Medical School

Research Program Affiliation

Member, Gynecologic Cancers

Member, Cancer Care Delivery Research

Research Abstract

I am a gynecologic oncologist at Beth Israel Deaconess Medical Center and an assistant professor in Obstetrics, Gynecology and Reproductive Medicine Harvard Medical School in Boston, MA. I completed my fellowship in Gynecologic Oncology in 2015 at Brigham and Women’s Hospital. I have also earned my Masters in Business Administration (M.B.A.) in healthcare management. I am most interested in health outcomes in gynecologic cancers, particularly patient-centered outcomes including financial hardship related to cancer care, value-based healthcare utilization and healthcare disparities. I have authored ten original research reports and co-authored many others. Several of these studies highlight my interest in examining the value of care in gynecologic malignancies and its economic impact from a healthcare system perspective and others in understanding the basic biology of gynecologic malignancies and associated gynecologic conditions such as endosalpingiosis. In my primary role as a clinician and surgeon, I have the privilege of caring for women at diagnosis and following them closely for years afterwards in surveillance, recurrence and end-of-life care. My healthcare management background also provides a unique opportunity to study the financial impact of cancer care in patients with gynecologic malignancies. In addition to helping individual patients navigate their disease process and the healthcare system, I aim to conduct research that will influence how other clinicians care for their patients and improve how patients understand the financial impact of their disease. I intend to develop a career as a clinical researcher that leverages my expertise in gynecologic oncology and my Masters in Business Administration, to evaluate patient-centered outcomes in gynecologic cancers and develop meaningful interventions with my translational collaborators to improve the value of care delivered to all patients.